A single trial readout just doubled a company’s market value in one session. Perplexity AI predicts the rerating continues, and the price prediction places Moderna at $180 to $240 by the end of 2026 with a $210 bullish base case.The catalyst is Intismeran, the personalized mRNA cancer vaccine. Perplexity calls it the dominant valuation driver […]
The post Perplexity AI Predicts Whether Moderna Stock Can Make Investors Rich in 2026 appeared first on Cryptonews.